|
Novo Nordisk Halts Hemophilia Drug’s Development, Three Others Remain
Novo Nordisk has discontinued development of one of its four hemophilia drug candidates following data from a Phase IIIa trial that found anti-drug antibodies and further potential risks for hemophilia patients with inhibitors.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives